Sava Handjiev

Nov 29, 2023 | bjcardio.co.uk | Jacob George |Prashasthi Devaiah |Sava Handjiev

Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK.